CORONAVIRUS

FDA Says Single-Dose Shot From J&J Prevents Severe COVID

Feb 24, 2021, 2:50 PM
FILE (Photo by Arnold Jerocki/Getty Images)...
FILE (Photo by Arnold Jerocki/Getty Images)
(Photo by Arnold Jerocki/Getty Images)

WASHINGTON (AP) — Johnson & Johnson’s single-dose vaccine offers strong protection against severe COVID-19, according to an analysis released Wednesday by U.S. regulators that sets the stage for a final decision on a new and easier-to-use shot to help tame the pandemic.

The long-anticipated shot could offer the nation a third vaccine option and help speed vaccinations by requiring just one dose instead of two. Food and Drug Administration scientists confirmed that overall the vaccine is about 66% effective at preventing moderate to severe COVID-19, and about 85% effective against the most serious illness. The agency also said J&J’s shot is safe.

The analysis is just one step in the FDA’s evaluation. On Friday, the agency’s independent advisers will debate if the evidence is strong enough to recommend the shot. With that advice, the FDA is expected to make a final decision within days.

The COVID-19 death toll in the U.S. topped 500,000 this week, and the vaccination drive has been slower than hoped, hampered by logistical and weather delays. So far, about 44.5 million Americans have received at least one dose of vaccine made by Pfizer or Moderna, and nearly 20 million of them have received the second dose required for full protection.

Tests showed the Pfizer and Moderna vaccines were 95% effective at protection against symptomatic COVID-19.

Dr. Paul Offit, a vaccine expert at Children’s Hospital of Philadelphia, is part of the FDA advisory panel that will scrutinize the J&J data on Friday and cautions that none of the vaccines have been directly compared. Still, he was encouraged that one dose of the J&J vaccine appears as good at preventing serious illness as its two-dose competitors.

“This is a vaccine to prevent you from going to the hospital and dying at a level that’s certainly comparable” to the Pfizer and Moderna vaccines, he said.

J&J tested its single-dose option in 44,000 adults in the U.S., Latin America and South Africa. Different mutated versions of the virus are circulating in different countries, and the FDA analysis cautioned that it’s not clear how well the vaccine works against each variant. But J&J previously announced that the vaccine worked better in the U.S. — 72% effective against moderate to severe COVID-19, compared with 66% in Latin America and 57% in South Africa.

South Africa recently began giving the J&J vaccine to front-line health workers on a test basis after deciding that a vaccine from rival AstraZeneca had not shown strong enough study results against the particularly concerning variant spreading there.

“I was reassured” that despite different variants, the J&J shot still protected against serious illness, said Dr. Jesse Goodman of Georgetown University, a former FDA vaccine chief. “That’s pretty robust data.”

Across all countries, Wednesday’s analysis showed protection began to emerge about 14 days after vaccination. But by 28 days after vaccination, there were no hospitalizations or deaths in the vaccinated group compared with 16 hospitalizations and seven deaths in study recipients who received a dummy shot.

The FDA said effectiveness and safety were consistent across racial groups, including Black and Latino participants.

All of the world’s COVID-19 vaccines have been tested differently, making comparisons nearly impossible. It would not be surprising if one dose turned out to be a little weaker than two doses, and policymakers will decide if that’s an acceptable trade-off to get more people vaccinated faster.

J&J has another large study underway to see if a second dose of its vaccine works better, raising the prospect that countries could eventually add a booster if one turned out to be warranted.

Like other COVID-19 vaccines, the main side effects of the J&J shot are pain at the injection site and flu-like fever, fatigue and headache. No study participant experienced the severe allergic reaction, called anaphylaxis, that is a rare risk of some other COVID-19 shots, although one experienced a less serious reaction.

The FDA said there were no serious side effects linked to the vaccine so far, although it recommended further monitoring for blood clots. In the study, those were reported in about 15 vaccine recipients and 10 placebo recipients, not enough of a difference to tell if the vaccine played any role.

J&J was on track to become the world’s first one-dose option until earlier this month. Mexico announced it would use a one-dose version from China’s CanSino, which is made with similar technology as J&J’s shot but initially was developed as a two-dose option until beginning a one-dose test in the fall.

The Pfizer and Moderna vaccines now being used in the U.S. and numerous other countries must be kept frozen, while the J&J shot can last three months in a refrigerator, making it easier to handle. AstraZeneca’s vaccine — widely used in Europe and Britain — is made similarly and also requires refrigeration but takes two doses.

If the FDA clears the J&J shot for U.S. use, it will not boost vaccine supplies significantly right away. Only a few million doses are expected to be ready for shipping in the first week. But J&J told Congress this week that it expected to provide 20 million doses by the end of March and 100 million by summer.

European regulators and the World Health Organization also are considering J&J’s vaccine. Worldwide, the company aims to produce around a billion doses by the end of the year.

___

Associated Press video producer Kathy Young contributed to this report.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

KSL 5 TV Live

Top Stories

Coronavirus

RSV and flu...
Deidre McPhillips, CNN

Flu season intensifies, holiday gatherings could make it worse

Americans gathered for Thanksgiving last week amid a flu season that's worse than any has been in more than a decade, and experts continue to urge caution as multiple respiratory viruses circulate at high levels nationwide.
23 hours ago
Protesters hold up blank papers and chant slogans as they march in protest in Beijing, Sunday, Nov....
Jessie Yeung and CNN's Beijing bureau

Rare protests are spreading across China. Here’s what you need to know

From Shanghai to Beijing, protests have erupted across China in a rare show of dissent against the ruling Communist Party.
23 hours ago
Police officers block Shanghai's Urumqi Road on Sunday. (Hector Retamal/AFP/Getty Images)...
CNN's Beijing bureau and Nectar Gan

Protests erupt across China in unprecedented challenge to Xi Jinping’s zero-Covid policy

Protests erupted across China throughout the weekend, including at universities and in Shanghai where hundreds chanted "Step down, Xi Jinping! Step down, Communist Party!"
2 days ago
Salt Lake City Police at the University of Utah Hospital due to a possible bomb threat. (Salt Lake ...
Michael Houck

Police: Unattended bag led to bomb squad response at U of U Hospital

Salt Lake City Police responded to a possible bomb threat at the University of Utah hospital Tuesday afternoon.
14 days ago
Evusheld...
Elizabeth Cohen and Naomi Thomas, CNN

COVID-19 medicine for immunocompromised patients is losing effectiveness

Judy Salins considers herself a smart, empowered patient, but until this week, she had no idea that the medicine she takes to defend herself against Covid-19 isn't protecting her as well as it used to.
18 days ago
Paxlovid, the antiviral pill that reduces the risk of hospitalization and death from Covid-19, also...
Jamie Gumbrecht, CNN

Paxlovid reduces risk of long Covid, Veterans Affairs study finds

Paxlovid, the antiviral pill that reduces the risk of hospitalization and death from Covid-19, also reduces the risk of long Covid, according to a new study by the US Department of Veterans Affairs.
23 days ago

Sponsored Articles

house with for rent sign posted...
Chase Harrington, president and COO of Entrata

Top 5 reasons you may want to consider apartment life over owning a home

There are many benefits of renting that can be overshadowed by the allure of buying a home. Here are five reasons why renting might be right for you.
Festive kitchen in Christmas decorations. Christmas dining room....
Lighting Design

6 Holiday Decor Trends to Try in 2022

We've rounded out the top 6 holiday decor trends for 2022 so you can be ahead of the game before you start shopping. 
Happy diverse college or university students are having fun on their graduation day...
BYU MBA at the Marriott School of Business

How to choose what MBA program is right for you: Take this quiz before you apply!

Wondering what MBA program is right for you? Take this quiz before you apply to see if it will help you meet your goals.
Diverse Group of Energetic Professionals Team Meeting in Modern Office: Brainstorming IT Programmer...
Les Olson

Don’t let a ransomware attack get you down | Protect your workplace today with cyber insurance

Business owners and operators should be on guard to protect their workplace. Cyber insurance can protect you from online attacks.
Hand turning a thermostat knob to increase savings by decreasing energy consumption. Composite imag...
Lighting Design

5 Lighting Tips to Save Energy and Money in Your Home

Advances in lighting technology make it easier to use smart features to cut costs. Read for tips to save energy by using different lighting strategies in your home.
Portrait of smiling practitioner with multi-ethnic senior people...
Summit Vista

How retirement communities help with healthy aging

There are many benefits that retirement communities contribute to healthy aging. Learn more about how it can enhance your life, or the life of your loved ones.
FDA Says Single-Dose Shot From J&J Prevents Severe COVID